false
Catalog
The Lead Episode 97: A Discussion of Pulmonary Vei ...
The Lead Episode 97 Speaker Information
The Lead Episode 97 Speaker Information
Back to course
Pdf Summary
The document outlines a discussion focused on comparing Pulmonary Vein Isolation (PVI) and a sham intervention for treating symptomatic atrial fibrillation. The discussion is hosted by Dr. Michael S. Lloyd from Emory University, with contributions from Dr. Harish Doppalapudi of the University of Alabama at Birmingham. It refers to a study published in the Journal of the American Medical Association by authors including Rajdip Dulai, Neil Sulke, and others. The study evaluates the effectiveness of PVI versus a sham procedure for atrial fibrillation. <br /><br />Both hosts, Dr. Lloyd and Dr. Doppalapudi, have disclosed their financial ties. Dr. Doppalapudi has received honoraria and consulting fees from several medical companies such as Boston Scientific and Abbott Medical, along with fellowship support from others like Medtronic and Biosense Webster. Dr. Lloyd has received payments for honoraria and consulting from Medtronic and is a member of advisory committees for Boston Scientific.<br /><br />The panel appears to offer insights into the controversial topic of PVI by looking at its efficacy compared to placebo treatments (sham interventions), which could influence treatment decisions for patients with symptomatic atrial fibrillation. This kind of discourse suggests a critical examination of current practices and emphasizes the importance of evidence-based approaches in healthcare.
Keywords
Pulmonary Vein Isolation
PVI
sham intervention
atrial fibrillation
Dr. Michael S. Lloyd
Dr. Harish Doppalapudi
Journal of the American Medical Association
Rajdip Dulai
Neil Sulke
evidence-based healthcare
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English